To understand whether IL-18 blockage following DNA vaccine plus α-GalCer-MPL combination limited vaccine efficacy in terms of the IFN- γ generated, and most importantly whether this would limit therapeutic effects against TC-1 tumor, C57BL/6 mice were administrated with anti-mouse IL-18 Ab, or isotype control mAb, 1 day prior to all of the vaccinations, and subsequently analyzed by the IFN-γ secretion and tumor volume. This evidence concerns the gene IL18 and neoplasm.